A Preliminary Study for INFORMED

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Heart FailureHeart Failure, DiastolicHeart Failure With Preserved Ejection FractionCardiac FailureHeart Diseases
Interventions
DRUG

Beta blocker

"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol"

DRUG

Beta blocker

"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol"

Trial Locations (1)

10065

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Weill Medical College of Cornell University

OTHER